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Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein
due to mutations of the dystrophin gene. Drisapersen is a 20-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in
dystrophin pre-mRNA to restore the reading frame of the mRNA. This study assessed safety, tolerability, and pharmacokinetics of
drisapersen after a single subcutaneous administration in non-ambulatory subjects. Eligible subjects were non-ambulant boys aged
P9 years, in wheelchairs for P1 to 64 years, with a diagnosis of DMD resulting from a mutation correctable by drisapersen
treatment. Four dose cohorts were planned (3, 6, 9 and 12 mg/kg), but study objectives were met with the 9 mg/kg dose. Less than
proportional increase in exposure was demonstrated over the 3–9 mg/kg dose range, though post hoc analysis showed dose
proportionality was more feasible over the 3–6 mg/kg range. Single doses of drisapersen at 3 and 6 mg/kg did not result in signiﬁcant
safety or tolerability concerns; however, at the 9 mg/kg dose, pyrexia and transient elevations in inﬂammatory parameters were seen.
The maximum tolerated dose of 6 mg/kg drisapersen was identiﬁed for further characterization in multiple dose studies in the
non-ambulant DMD population.
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Open access under C1. Introduction
Duchenne muscular dystrophy (DMD) is an inheritable,
X chromosome-linked lethal childhood disease with an
incidence of approximately 1 in 3500 newborn boys [1].
DMD is caused by mutations in the gene coding for the
protein dystrophin resulting in little or no dystrophin
being produced. Dystrophin is essential for the integrityC BY-NC-ND license.
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dystrophin leads to progressive muscle weakness, with
DMD patients typically wheelchair-bound before the age
of 12. As the disease progresses, respiratory and cardiac
muscles are aﬀected, orthopedic complications occur,
and, in the absence of intervention, death occurs at
approximately age 19 [4]. Current supportive treatments
include physiotherapy, mechanical supports, orthopedic
surgery, assisted ventilation, disease management (e.g.,
for respiratory infections, cardiomyopathy) and
glucocorticosteroids. This multidisciplinary approach to
treatment has prolonged life expectancy, with some
patients surviving into the fourth decade and beyond [4,5].
In DMD, genetic mutations, such as a deletion of one or
more exons, result in an out-of-frame transcription product
and subsequent disrupted dystrophin protein synthesis [6].
The aim of oligonucleotide-based therapy is to manipulate
the post-transcriptional splicing process of the pre-mRNA
in such a way that the reading frame of the resulting
mRNA is restored. This would result in the production
of a shortened yet partially functional dystrophin protein,
analogous to that seen in the less severe Becker muscular
dystrophy (BMD). Such treatment could potentially
delay disease progression and improve function in the
remaining muscle [7].
Drisapersen (formerly GSK2402968 and PRO051) is a
20mer chemically-modiﬁed (20-O-methyl-phosphorothioate)
oligonucleotide with a sequence optimized to skip exon 51 in
the human dystrophin pre-mRNA. Mutations thought to be
correctable by skipping exon 51 account for approximately
13% of all DMD patients [8]. Drisapersen has been shown to
induce novel dystrophin production after both local injection
[9] and systemic administration [10], and weekly
subcutaneous drisapersen treatment (6 mg/kg/week) has
shown encouraging results on functional endpoints,
including the 6 Minute Walk Distance (6MWD) test [10].
The eﬃcacy and safety of drisapersen is currently being
studied in ambulant boys with DMD in several clinical
trials worldwide [11–15]; however, there has been limited
experience in non-ambulant boys with DMD. Since
muscle potentially accounts for a large proportion of
uptake of drisapersen, there is the potential that the
pharmacokinetics of drisapersen may be diﬀerent in the
non-ambulant DMD population due to reduced lean
muscle mass relative to ambulant boys. The purpose of
the current study (DMD114118; ClinicalTrials.gov
Identiﬁer: NCT01128855) was to assess the safety,
tolerability, and pharmacokinetics of drisapersen after a
single subcutaneous administration at diﬀerent dose levels
in non-ambulant subjects with DMD.
2. Patients and methods
Eligible subjects were non-ambulant boys agedP9 years,
in wheelchair for at least one year but no more than 4 years,
and with a diagnosis of DMD resulting from a mutation
correctable by treatment with drisapersen. Patients withadditional mutations not correctable by drisapersen, with
a history of renal or hepatic disease, or with symptomatic
cardiomyopathy were excluded. Treatment with
glucocorticosteroids was allowed, but these had to be
started at least 6 months and have been dosed with a
stable regimen for at least 3 months before the anticipated
ﬁrst administration of study medication. Use of
anticoagulants, antithrombotics or antiplatelet agents,
previous treatment with investigational drugs within
6 months of the ﬁrst administration of study medication,
and use of idebenone or other forms of Coenzyme Q10
within 1 month of study medication was prohibited.
Following a screening period of up to 2 weeks, subjects
were randomized to receive a single subcutaneous dose of
drisapersen or dose-matched placebo. Subjects were
assigned to study treatment in accordance with a central
randomization schedule. In each cohort, subjects were
randomized to a single dose level of drisapersen or
dose-matched placebo, in a ratio of 3:1. Drisapersen was
supplied as a solution for subcutaneous injection,
200 mg/mL. The precise amount administered was
titrated against body weight in accordance with the
protocol instructions. The study was designed to enroll
up to 32 subjects within 4 cohorts, with the ﬁnal 2
cohorts being divided into 2 sub-groups (1, 2, 3a/3b, 4a/
4b). Each planned cohort was comprised of 8 subjects (6
active and 2 placebo) not to exceed the following levels:
 Cohort 1: 3 mg/kg drisapersen or placebo;
 Cohort 2: 6 mg/kg drisapersen or placebo;
 Cohort 3: 9 mg/kg drisapersen or placebo;
 Cohort 4: 12 mg/kg drisapersen or placebo
Cohorts 3 and 4 were divided into sub-groups 3a/3b and
4a/4b, with 4 subjects in each sub-group. All subjects in
Cohort 3 (3a and 3b) were planned to receive up to
9 mg/kg, and all subjects in Cohort 4 (4a and 4b) were
planned to receive up to 12 mg/kg. There was planned to
be at least 14 days between treating the last subject of
sub-group a and treating the ﬁrst subject in sub-group b,
with safety parameters reviewed prior to moving to
subgroup b.
The study allowed dose levels in subsequent cohorts to
be modiﬁed downwards or repeated at the same dose of
the previous cohort following review of data by a Safety
Review Team. Subjects had a 1 month active study
period and a 5 month post-dose follow-up period.
The primary pharmacokinetic (PK) endpoints included:
area under the plasma concentration–time curve (AUC)
from time 0 to 24 h post-dose (AUC0–24h), and time 0 to
7 days post-dose (AUC0–7d); the observed maximum
plasma concentration post-dose (Cmax); and the time of
maximum plasma concentration post-dose (Tmax). The
primary safety and tolerability endpoints included:
adverse event (AE) monitoring; 12-lead ECG; vital signs;
laboratory safety tests (biochemistry, hematology,
urinalysis and coagulation parameters); and local
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single central laboratory.
3. Results
A total of 21 subjects were screened, of whom 20 were
randomized into the study at 2 study sites, one in the US
(n = 16 subjects), and one in France (n = 4 subjects). All
randomized subjects completed the study. It was
concluded that the study objectives had been met
following analysis of cohort 3a and a decision was taken
after completion of the ﬁrst 9 mg/kg cohort not to
proceed to the next 9 mg/kg cohort (see discussion
below). Therefore, only the results for these completed
cohorts are reported.
Table 1 shows the baseline characteristics of the study
population, including concomitant medications. No
major diﬀerences were observed across treatment groups
in demographic characteristics with two exceptions: the
6 mg/kg drisapersen treatment group on average weighed
more than the other 3 treatment groups and the 9 mg/kg
drisapersen treatment group were younger on average
than the other 3 treatment groups. The duration of time
since ﬁrst DMD symptoms, time since ﬁrst diagnosis and
time since loss of ambulation were similar across groupsTable 1
Subject baseline characteristics, including concomitant medications.
Number of Subjects Placebo 3 mg/kg
Number of subjects planned, N: 5 6
Number of subjects randomized, N: 5 6
Number of subjects withdrawn, n (%): 0 0
Age in years
Mean (SD) 12.2 (0.84) 13.8 (1.
Median 12.0 13.0
Min, Max 11, 13 12, 16
Weight (kg)
Mean (SD) 49.10 (13.99) 50.45 (1
Median 51.20 49.85
Min, Max 28.6, 64.4 31.9, 73
Height (cm)
Mean (SD) 147.6 (23.88) 149.5 (1
Median 135.0 149.0
Min, Max 122, 176 137, 165
Time since ﬁrst symptoms (months)
Mean (SD) 123.4 (15.09) 132.4 (2
Median 124.4 131.4
Time since diagnosis (months)
Mean (SD) 110.2 (16.56) 116.0 (1
Median 111.7 120.1
Time since loss of ambulation (months)
Mean (SD) 25.3 (11.22) 36.5 (10
Median 21.8 38.6
Any medication, n (%)
Glucocorticosteroids 3 (60) 3 (50)
ACE Inhibitors 4 (80) 3 (50)
Beta blockers 1 (20) 2 (33)with the exception of the 9 mg/kg drisapersen treated
group which had a shorter duration for all of these
characteristics. The majority of subjects were treated with
glucocorticosteroids.
3.1. Pharmacokinetic results
The pharmacokinetics of single subcutaneous injections
of drisapersen in non-ambulant subjects with DMD were
assessed in this study at doses of 3, 6 and 9 mg/kg
(Table 2). When analyzing all data from all doses for
dose proportionality, dose proportionality was not
demonstrated over the range of 3–9 mg/kg, although a
post hoc analysis showed that the proportionality is more
feasible over the range of 3–6 mg/kg than the 3–9 mg/kg
range (Table 3).
Since antisense oligonucleotides like drisapersen are
known to distribute into adipose tissue, and non-
ambulant boys with DMD generally have a high
percentage body fat as compared to healthy or ambulant
boys with DMD, the relation between body fat and
exposure was explored. Plotting Cmax and AUC(0–24)
versus the percentage body fat showed no relationship
between these PK parameters over the range of body fat
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Table 2
Summary of selected drisapersen pharmacokinetic parameters.
Parameter n 3 mg/kg Drisapersen n 6 mg/kg Drisapersen n 9 mg/kg Drisapersen
Cmax (ng/mL)a 6 4990 (36.0) 6 8140 (25.9) 3 8940 (20.8)
AUC(0–24) (ng.hr/mL)a 6 44,600 (18.5) 6 87,800 (33.4) 3 97,800 (10.7)
AUC(0–168) (ng.hr/mL)a 4 45,500 (16.0) 3 87,300 (18.7) 2 112000 (0.6)
Tmax (hr)b 6 3.01 (2.97–5.78) 6 3.00 (2.98–6.00) 3 6.00 (3.00–6.00)
a Geometric mean (CV%).
b Median (range).
Table 3
Summary of results of statistical analysis to estimate dose proportionality after single doses of drisapersen.
Parameter n Adjusted mean slope Standard error 90% Conﬁdence interval for slopea, b
Drisapersen 3–9 mg/kg
Cmax 15 0.581 0.1712 (0.278–0.884)
AUC(0–24) 15 0.791 0.1505 (0.524–1.057)
AUC(0–168) 9 0.848 0.1107 (0.638–1.058)
Drisapersen 3–6 mg/kg only (Post hoc analysis)
Cmax 12 0.705 0.2547 (0.243–1.167)
AUC(0–24) 12 0.977 0.2201 (0.578–1.376)
AUC(0–168) 7 0.939 0.1871 (0.562–1.316)
a For single doses of drisapersen 3–9 mg/kg, dose proportional range was 0.797–1.203 for all parameters.
b For single doses of drisapersen 3–6 mg/kg only, dose proportional range was 0.678–1.322 for all parameters.
Fig. 1. Pharmacokinetic parameters versus body fat.
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Table 4
Summary of all adverse events by treatment.




Drisapersen (N = 6)
6 mg/kg
Drisapersen (N = 6)
9 mg/kg
Drisapersen (N = 3)
Total
(N = 20)
Any AE by phase
Treatment emergent 2 (40) 6 (100) 6 (100) 3 (100) 17 (85)
Follow-up 2 (40) 3 (50) 4 (67) 0 9 (45)
Drug related AEs (per investigator judgment) 1 (20) 5 (83) 5 (83) 3 (100) 14 (70)
AEs of special interest
Injection site reaction 1 (20) 4 (67) 5 (83) 3 (100) 13 (65)
Renal toxicity 0 0 0 1 (33) 1 (5)
Inﬂammation 0 0 1 (17) 3 (100) 4 (20)
Table 5
Summary of adverse events of special interest by treatment.
Special interest category preferred term Placebo (N = 5) 3 mg/kg Drisapersen (N = 6) 6 mg/kg Drisapersen (N = 6) 9 mg/kg Drisapersen (N = 3)
Injection site reaction, any event, n (%) 1 (20) 4 (67) 5 (83) 3 (100)
Injection site discoloration 1 (20) 3 (50) 5 (83) 3 (100)
Injection site induration 1 (20) 3 (50) 4 (67) 2 (67)
Injection site erythema 0 3 (50) 1 (17) 2 (67)
Injection site hematoma 0 1 (17) 2 (33) 1 (33)
Injection site inﬂammation 0 0 1 (17) 3 (100)
Injection site edema 0 0 0 2 (67)
Injection site pruritus 0 2 (33) 0 0
Injection site pain 0 1 (17) 0 0
Injection site warmth 0 0 1 (17) 0
Renal Toxicity, any event, n (%) 0 0 0 1 (33)
Alpha 1 microglobulin increaseda 0 0 0 1 (33)
Inﬂammation, any event, n (%) 0 0 1 (17) 3 (100)
Pyrexia 0 0 1 (17) 3 (100)
C reactive protein increasedb 0 0 0 1 (33)
Immunology test abnormalc 0 0 0 1 (33)
a Laboratory reference range: less than 12.0 mg/L.
b Laboratory reference range: 0–3.0 mg/L.
c Increase in complement split products.
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No deaths, serious adverse events (SAEs), or
withdrawals were reported on the study. Adverse events
(AEs) for this study were classiﬁed into treatment
emergent AEs and follow-up AEs. Treatment emergent
AEs were deﬁned as AEs occurring from the start of
study treatment up to and including Day 28. Follow-up
AEs were deﬁned as those AEs beginning from Day 29
up to and including the ﬁnal follow-up contact (5 months
after administration of study treatment). AEs of special
interest were deﬁned as injection site reactions, hepatic
toxicity, renal toxicity, thrombocytopenia, inﬂammatory
reactions, and coagulation abnormalities. These were
deﬁned based on hazards identiﬁed in clinical and
preclinical studies of drisapersen. The summary of all
AEs is shown in Table 4. All subjects receiving
drisapersen experienced at least 1 treatment emergent
AE, the majority of which were considered drug related,
compared to 2 subjects (40%) receiving placebo, 1 of
whom reported an AE considered to be drug related. Theincidence of follow-up phase AEs was variable across the
treatment groups and was less frequent than in the
treatment phase. The only AE occurring in P2 subjects
in any group that was not an AE of special interest was
headache, which occurred in 1 subject in each of the
placebo, 3 mg/kg and 6 mg/kg active groups and in 2
subjects in the 9 mg/kg active group. A summary of all
AEs of special interest is shown in Table 5. A higher
percentage of injection site reactions were reported in the
drisapersen treated groups compared to placebo, with
increasing proportions with increasing dose. Renal AEs
(a1-microglobulin increased) were seen only in the 9
mg/kg treated group. Inﬂammatory AEs were seen in
both the 6 mg/kg (1 subject, 17%) and 9 mg/kg treatment
groups (3 subjects, 100%). No hepatic toxicity,
thrombocytopenia, or coagulation abnormalities were
reported.
All study subjects had elevated ALT and AST values at
baseline, and there were no eﬀects seen during the
treatment period. Boys with DMD typically have
elevations in ALT and AST due to leakage from muscle
Table 6
Summary of mean and median urine a-1-microglobulin values over time.
Lab Test Treatment N Visit n Mean (SD) Median (Range)
Urine alpha 1 microglobulin (mg/L) Placebo 5 Screening 3 5.70 (0.000) 5.70 (5.7–5.7)
Day 1 5 6.14 (0.984) 5.70 (5.7–7.9)
Day 8 5 5.70 (0) 5.70 (5.7–5.7)
Follow-up 5 7.76 (3.871) 5.70 (5.7–14.6)
3 mg/kg Drisapersen 6 Screening 3 5.70 (0.000) 5.70 (5.7–5.7)
Day 1 6 5.70 (0.000) 5.70 (5.7–5.7)
Day 8 6 7.27 (2.563) 5.70 (5.7–11.7)
Follow-up 6 5.70 (0) 5.70 (5.7–5.7)
6 mg/kg Drisapersen 6 Screening 0 No data No data
Day 1 6 5.78 (0.204) 5.70 (5.7–6.2)
Day 8 6 16.83 (11.767) 14.05 (5.7–31.0)
Follow-up 6 6.82 (2.735) 5.70 (5.7–12.4)
9 mg/kg Drisapersen 3 Screening 0 No data No data
Day 1 2 5.70 (0.000) 5.70 (5.7–5.7)
Day 8 3 31.03 (12.974) 25.20 (22.0–45.9)
Follow-up 3 5.70 (0) 5.70 (5.7–5.7)
Laboratory Reference range for urine alpha 1 microglobulin: less than 12.0 mg/L.
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total bilirubin, gamma glutamyl transferase (GGT), and
glutamate dehydrogenase (GLDH) values in each
drisapersen treated cohort remained within the
established reference range throughout the study. No
urinary protein increases were seen post dose in the 3 and
6 mg/kg groups, but the placebo and, of greater
magnitude, the 9 mg/kg treated groups had increases in
random urine protein values at Day 8 compared with
pre-dose values (placebo: Day 1, 169.8 ± 89.4 mg/L; Day
8, 185.4 ± 123.6 mg/L; 9 mg/kg: Day 1, 86.5 ± 51.6
mg/L; Day 8, 205.0 ± 99.6 mg/L). These values declined
by the follow-up visit. Serum cystatin C values remained
within normal limits. Elevations in mean urine
a1-microglobulin values were seen in all drisapersen
treated groups over the course of the study up to Day 8.Fig. 2. Mean proﬁle plot of high sensiThese changes appeared dose dependent and reversible
(Table 6). A slight decrease in mean platelet
measurements was observed immediately following
dosing (Day 2) in all groups; however all values stayed
within the normal reference range and returned to
pre-dose levels by Day 8. All aPTT values remained
within the established reference range for all treatment
groups except the 9 mg/kg drisapersen treated group,
which had 3 h post-dose values higher than the upper
limit of normal (35.0 ± 2.8 s; reference range: 22–34 s).
All of the aPTT values for the 9 mg/kg group returned to
within normal limits by 6 h post-dose. Other hematology
and biochemistry values were unremarkable.
Several inﬂammatory biomarkers were measured in the
study, including: high sensitivity C-reactive protein
(hsCRP); monocyte chemotactic protein-1 (MCP-1);tivity C-reactive protein (hsCRP).
Fig. 3. Mean proﬁle plot of monocyte chemotactic protein-1 (MCP-1).
Fig. 4. Mean proﬁle plot of interleukin-6 (IL-6).
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complement split factors C3a, Bb, and SC5b-9;
ﬁbrinogen; and haptoglobin. Across treatment groups,
there were ﬂuctuations in complement split factors C3a,
and SC5b-9 and in TNF-a but no clear trends were
observed. In the 3 and 6 mg/kg drisapersen treated
groups, reversible changes were observed post-dose for
complement split factor Bb, hsCRP, ﬁbrinogen,
haptoglobin, IL-6 and MCP-1. These returned to baseline
between 6 h and 1 week post-dose suggesting a low local
inﬂammatory response to administration of product. In
the 9 mg/kg drisapersen treated group, 1 subject had
values of hsCRP >2  ULN and 2  baseline value. Inaddition, all 3 subjects treated with 9 mg/kg drisapersen
had fever and elevations of other inﬂammatory
biomarkers (predominantly hsCRP, MCP-1 and IL-6)
(Figs. 2–4). Although transient increases were also seen
for these parameters in the 6 mg/kg group, these were
generally less than for the 9 mg/kg group. The highest
temperature recorded by the investigator in the 9 mg/kg
group was 37.9 C; however temperatures up to 39.0 C
were reported to the investigators by the subject’s
families (measured outside of study procedures). These
reportedly occurred in 2 subjects approximately 20 h and
30 h after dosing and resolved without sequelae. All other
vital signs were within normal ranges for all groups.
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observed at any time throughout the study for any
treatment group.
4. Discussion
This study was the ﬁrst double-blind placebo-controlled
study to administer drisapersen in non-ambulant DMD
subjects. This study was also the ﬁrst time doses higher
than 6 mg/kg of drisapersen have been administered in
the DMD population. The study showed that single
doses of 3 and 6 mg/kg were generally well tolerated, but
that the 9 mg/kg dose was limited by acute (though
self-resolving) inﬂammatory responses. Additionally, the
9 mg/kg dose did not oﬀer any apparent increase in
exposure as compared to the 6 mg/kg dose.
Pharmacokinetic analysis demonstrated less than
proportional increase in exposure (in terms of AUC) over
the dose range of 3–9 mg/kg, though post hoc analysis
showed that proportionality was more feasible over the
3–6 mg/kg range than the 3–9 mg/kg range. The reason
for the observed non-proportionality cannot be
concluded from this study. It may be related to
absorption saturation at the higher dose, since the slope
of Cmax with dose is lower than that of AUC, indicating
that it might be related to absorption rather than
distribution or elimination. The later Tmax as observed
after 9 mg/kg (6 h compared to 3 h for the 3 and 6 mg/kg
doses) seems to be in line with this hypothesis.
The pharmacokinetics of drisapersen after a single
subcutaneous dose of 6 mg/kg were similar between
non-ambulant subjects in the current study and ambulant
subjects in the Goemans et al. [10] study. Since a dose of
3 mg/kg was not tested in the previous study [10], the
results of this dose could not be compared. However, the
data of the 2 and 4 mg/kg doses that were tested in
the Goemans et al. study [10] indicated that the lower
dose also resulted in similar PK between the ambulant
and non-ambulant population. Although in the current
study t1/2 could not be calculated, this comparable PK
between the two studies indicates that the PK at steady
state after multiple dosing at doses up to 6 mg/kg in non-
ambulant subjects may also be similar to that observed in
ambulant subjects.
Since antisense oligonucleotides like drisapersen are
known to distribute into adipose tissue, and
non-ambulant boys with DMD generally have a high
percentage body fat, the relation between body fat and
exposure was explored. Plotting Cmax and AUC(0–24)
versus the percentage body fat showed that these PK
parameters appeared constant over the range of body fat
percentages tested. It should be noted that data from
younger boys, who are likely to have lower body fat
percentages, should be included in order to make a
deﬁnitive conclusion, but from the data collected within
this study, no relationship between percentage body fat
and PK of drisapersen have been observed.Single doses of drisapersen at 3 mg/kg and 6 mg/kg did
not result in signiﬁcant safety or tolerability concerns in the
non-ambulant DMD population. Adverse events and
laboratory abnormalities were similar to those reported
to date in the previous open-label drisapersen DMD
study [10].
Drisapersen at the 9 mg/kg dose showed tolerability
issues (pyrexia) in the treated subjects. As dose
proportionality in PK was not demonstrated in this
study, it is unknown why these occurred at this dose
level. Although the reason for lower tolerability of the
drisapersen 9 mg/kg dose is not known, it is possible that
the larger volume of administration, the greater local
drug exposure, and/or the need for more than a single
injection could result in an increased risk of local
inﬂammatory reactions. This could then be complicated
by inﬂammatory biomarker release with subsequent
pyrexia.
Injection site reactions were also seen across the
drisapersen and placebo groups, though with a higher
incidence in the active treatment group. This ﬁnding is
consistent with what has previously been observed in
predominantly ambulant boys [10].
Antisense oligonucleotides such as drisapersen have
known preclinical class eﬀects. These fall into four
main categories: inﬂammation, thrombocytopenia,
accumulation in the kidneys and liver, and increases in
aPTT. With the exception of pyrexia reported in one
subject who received drisapersen 6 mg/kg, subjects
receiving drisapersen at doses of 3 mg/kg and 6 mg/kg
did not experience any AEs related to class eﬀects. In
contrast, all subjects receiving 9 mg/kg drisapersen
experienced AEs suggestive of inﬂammation together with
increases in hsCRP, MCP-1 and IL-6. Although transient
increases were also seen for these parameters in the 6 mg/
kg group, these were generally less than for the 9 mg/kg
group. These eﬀects were time-limited and self-resolving,
without any further clinical sequelae. A repeat dose study
in ambulant subjects treated at 6 mg/kg/week did not
show evidence of acute or persistent systemic
inﬂammatory responses [10].
Elevations in mean urine a1-microglobulin values were
seen in all groups up to Day 8. These changes appeared
dose dependant and reversible. Increases in
a1-microglobulin were also seen in the repeat dose study
of predominantly ambulant boys [10], and possibly
represent an adaptive process within renal tubules (which
may absorb oligonucleotides).
It was concluded that the study objectives had been met
following analysis of cohort 3a (9 mg/kg) and the decision
was made not to proceed to cohort 3b (9 mg/kg) or cohort
4 (12 mg/kg). The study was considered to have met the
objectives of the study because: (1) doses of 3 mg/kg and
6 mg/kg were generally well tolerated; (2) there were less
than proportional increases in exposure from 6 to 9 mg/
kg, suggesting that investigation of higher doses
administered subcutaneously would not likely lead to
24 K.M. Flanigan et al. /Neuromuscular Disorders 24 (2014) 16–24increased systemic exposure; and (3) tolerability at the
9 mg/kg dose was limited by acute (though self-resolving)
inﬂammatory reactions.
Therefore, the maximum tolerated dose of 6 mg/kg of
drisapersen was identiﬁed for further characterization in
multiple dose studies in the non-ambulant DMD
population. This ﬁnding is consistent with those from the
ambulant DMD population, where the dose of 6 mg/kg/
week is being studied in double-blind, placebo-controlled,
24–48 week studies of the eﬃcacy and safety of drisapersen.
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